LGND — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
$293.81
Market Cap
$5.86B
52W High
$326.63
52W Low
$175.89
ADV30
222,362
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 78,746,000 | 76,096,000 | -9,491,000 | -28,485,000 | 2,237,462,000 | 55,958,000 | 1,275,699,000 |
| Jun 2026 | 63,693,000 | 60,479,000 | 8,591,000 | 48,508,000 | 2,185,875,000 | 1,006,702,000 | 1,218,359,000 |
| Mar 2026 | 51,722,000 | 48,449,000 | 17,368,000 | -13,345,000 | 1,532,105,000 | 115,077,000 | 534,783,000 |
| Dec 2025 | 59,666,000 | 56,674,000 | 20,040,000 | 44,784,000 | 1,560,637,000 | 174,927,000 | 543,425,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$131,714,000
Investing CF
$-144,779,000
Financing CF
$950,276,000
CapEx
$-11,959,000
Dividends Paid
—
Buybacks
$-15,000,000
EPS Diluted TTM
$9.35
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$583,251,000
Inventory
$8,663,000
Receivables
$69,922,000
ST Investments
$364,038,000
EBIT TTM
$244,152,000
Pretax Income TTM
$237,962,000
Interest Exp TTM
$6,190,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$306,899,008
EBITDA
$117,036,000
Free Cash Flow
$139,748,880
Enterprise Value
$7,123,557,376
Total Cash
$447,395,008
Total Debt
$1,128,216,960
Shares Out
19,935,609
Trailing EPS
$9.49
Book Value
$48.57
ROE
5.4%
ROA
2.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 268,087,000 | 47,199,000 | 124,453,000 | 1,560,637,000 | 543,425,000 | 1,017,212,000 | 49,359,000 |
| Dec 2024 | 167,133,000 | 23,021,000 | -4,032,000 | 941,774,000 | 111,335,000 | 830,439,000 | 97,047,000 |
| Dec 2023 | 131,314,000 | 9,821,000 | 52,154,000 | 787,216,000 | 86,303,000 | 700,913,000 | 49,577,000 |
| Dec 2022 | 196,245,000 | 3,037,000 | -33,361,000 | 762,668,000 | 165,183,000 | 597,485,000 | 137,850,000 |
TTM Snapshot
Revenues TTM
$290,542,000
NetIncome TTM
$197,220,000
OpCashFlow TTM
—
Assets (Latest)
$2,185,875,000
Forward EPS
$11.96
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $290.00 · spot: $298.71 · call volume: 95 · put volume: 66Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $6.00B | $91.95 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $6.08B | $42.99 | — |
| BLTE | BELITE BIO, INC | $6.35B | $157.72 | — |
| GIFLF | Grifols SA | $5.37B | $12.72 | — |
| MANE | Veradermics, Inc | $5.30B | $125.64 | — |
News headlines (Yahoo Finance, 1h cache)
Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says
2026-10-30 17:12 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength
2026-10-30 17:09 · Yahoo
Ligand (LGND) Q3 2026 Earnings Call Transcript
2026-10-30 14:46 · Yahoo
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
2026-10-29 19:14 · Yahoo
Ligand: Q3 Earnings Snapshot
2026-10-29 11:20 · Yahoo
Ligand Reports Third Quarter 2026 Financial Results
2026-10-29 11:00 · Yahoo
Ligand to Participate in November Investor Conferences
2026-10-27 20:01 · Yahoo
Ligand to Host Investor Day on December 8, 2026
2026-10-22 20:01 · Yahoo
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
2026-10-19 15:42 · Yahoo
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
2026-10-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.